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Platelets are specialized anucleate cells that play a key role
in hemostasis through their ability to rapidly adhere to
subendothelial matrix proteins and endothelial cells
(platelet adhesion) and to other activated platelets (plate-
let aggregation). The importance of cyclic nucleotides and
especially the NO-cGMP-PKG pathway as potent inhibi-
tors of platelet activation has been well established by
many investigators in human and animal platelets. How-
ever, recently a new mechanism of platelet activation by
vWF, mediated by PKG (that sequentially activates p38
and ERK MAP kinases), was proposed [1,2]. Here we
present data that activation of PKG by cGMP analogs or
NO donors does not stimulate, but rather inhibits, p38
and ERK MAP kinases [3]. However, some PKG stimula-
tors and inhibitors do affect platelets independently of
PKG activity [4]. Our data also show that human and
mouse platelets do not express functionally active eNOS.
However, activation of the vWF receptor in human and
mouse platelets stimulates basal guanylyl cyclase activity
independently of NOS activation. Furthermore, a PDE5
inhibitor (sildenafil) increases cGMP content in both
eNOS KO and WT mouse platelets, whereas in mouse
aorta (in which sGC activity is strongly eNOS-dependent),
sildenafil increased cGMP only in WT but not eNOS KO
mice. In summary, our data do not provide any evidence
for a "stimulatory role" of PKG in platelets. Our data sug-
gest that vWF-induced increase in platelet cGMP is inde-
pendent of platelet eNOS activity and may involve
regulation of basal sGC activity by tyrosine phosphoryla-
tion.
Acknowledgements
This work was supported by the Deutsche Forschungsgemeinschaft (SFB 
688).
References
1. Li Z, Xi X, Gu M, Feil R, Ye RD, Eigenthaler M, Hofmann F, Du X: A
stimulatory role for cGMP-dependent protein kinase in
platelet activation.  Cell 2003, 112:77-86.
2. Li Z, Zhang G, Feil R, Han J, Du X: Sequential activation of p38
and ERK pathways by cGMP-dependent protein kinase lead-
ing to activation of the platelet integrin alphaIIb beta3.  Blood
2006, 107:965-972.
3. Begonja AJ, Geiger J, Rukoyatkina N, Rauchfuss S, Gambaryan S, Wal-
ter U: Thrombin stimulation of p38 MAP kinase in human
platelets is mediated by ADP and thromboxane A2 and
inhibited by cGMP/cGMP-dependent protein kinase.  Blood
2007, 109:616-618.
4. Gambaryan S, Geiger J, Schwarz UR, Butt E, Begonja A, Obergfell A,
Walter U: Potent inhibition of human platelets by cGMP ana-
logs independent of cGMP-dependent protein kinase.  Blood
2004, 103:2593-2600.
from 3rd International Conference on cGMP Generators, Effectors and Therapeutic Implications
Dresden, Germany. 15–17 June 2007
Published: 25 July 2007
BMC Pharmacology 2007, 7(Suppl 1):S50 doi:10.1186/1471-2210-7-S1-S50
<supplement> <title> <p>3<sup>rd </sup>International Conference on cGMP Generators, Effectors and Therapeutic Implications</p> </title> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1471-2210-7-S1-full.pdf">here</a>.</note> </supplement>
This abstract is available from: http://www.biomedcentral.com/1471-2210/7/S1/S50
© 2007 Gambaryan et al; licensee BioMed Central Ltd. 
